참고문헌
- T. J. Liang, "Hepatitis B: the virus and disease", Hepatology, Vol. 49, pp. S13-S21, 2009. https://doi.org/10.1002/hep.22881
- N. Gitilin, "HepatitisB: diagnosis, prevention and treatment", Clin. Chem., Vol. 43, pp. 1500-1506, 1997.
- M. Rizzetto and A. Ciancio, "Chronic HBV-related liver disease", Mol. Aspects Med., Vol. 29, pp. 72-84, 2008. https://doi.org/10.1016/j.mam.2007.09.013
- N. Liu, F. Zhao, H. Jia, D. Rai, P. Zhan, X. Jiang, and X. Liu, "Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations", Med. Chem. Commun., Vol. 6, pp. 521-535, 2015. https://doi.org/10.1039/C4MD00521J
- D. Lavanchy, "Hepatitis B virus epidemiology, disease burden, treatment, current and emerging prevention and control measures", J. Viral Hepatitis, Vol.11, pp. 97-107, 2004. https://doi.org/10.1046/j.1365-2893.2003.00487.x
- K. H. Kim, N. D. Kim, and B. L. Seong, "Discovery and development of anti-HBV agents and their resistance", Molecules, Vol. 15, pp. 5878-5908, 2010. https://doi.org/10.3390/molecules15095878
- Y. Li, L. Fu, H. Yeo, J. L. Zhu, C. K. Chou, Y. H. Kou, S. F. Yeh, E. Gullen, D. Austin, and Y. C. Cheng, "Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative", Antiviral Chemistry & Chemotherapy, Vol. 16, pp. 193-201, 2005. https://doi.org/10.1177/095632020501600305
- E. De Clercq, G. Ferir, S. Kaptein, and J. Neyts, "Antiviral treatment of chronic hepatitis B virus (HBV) infections", Viruses, Vol. 2, pp.1279-1305, 2010. https://doi.org/10.3390/v2061279
- H. Kwon and A. S. Lok, "Hepatitis B therapy", Nat. Rev. Gastro. Hepat., Vol. 8, pp. 275-284, 2011. https://doi.org/10.1038/nrgastro.2011.33
- T. M. Block, R. Gish, H. Guo, A. Mehta, A. Cuconati, W. T. London, and J. Guo, "Chronic hepatitis B: what should be the goal for new therapies?", Antivir. Res., Vol. 98, pp. 27-34, 2013. https://doi.org/10.1016/j.antiviral.2013.01.006
- B. Liu, X. Wen, C. Huang, and Y. Wei, "Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years", Int. J. Biochem. Cell B., Vol. 45, pp. 1987-1996, 2013. https://doi.org/10.1016/j.biocel.2013.06.017
- K. Sato and M. Mori, "Current and novel therapies for Hepatitis B virus infection", Mini-Rev. Med. Chem., Vol. 10, pp. 20-31, 2010. https://doi.org/10.2174/138955710791112613
- F. Zoulim and S. Locarnini, "Management of treatment failure in chronic hepatitis B", J. Hepatol., Vol. 56, pp. S112-S122, 2012.
- A. S. Lok, "Combination Nucleos(t)ide Analogue as Initial Treatment for Chronic Hepatitis B: Have We Put This to Rest?", Hepatology, Vol. 58, pp. 483-485, 2013. https://doi.org/10.1002/hep.26337
- P. R. Daga, J. Duan, and R. J. Doerksen, "Computational model of hepatitis B virus DNA polymerase: Molecular dynamics and docking to understand resistant mutations", Protein Sci., Vol. 19, pp. 796-807, 2010. https://doi.org/10.1002/pro.359
- S. Locarnini, and W. S. Mason, "Cellular and virological mechanisms of HBV drug resistance", J. Hepatol., Vol. 44, pp. 422-431, 2006. https://doi.org/10.1016/j.jhep.2005.11.036
- F. Perveen, R. Qureshi, F. L. Ansari, S. Kalsoom, and S. Ahmed, "Investigations of drug-DNA interactions using molecular docking, cyclic voltammetry and UV-Vis spectroscopy", J. Mol. Struct., Vol. 1004, pp. 67-73, 2011. https://doi.org/10.1016/j.molstruc.2011.07.027
- B. Sathya, "Molecular docking study of naturally-derived neuraminidase inhibitors isolated from phellinus baumii", J. Chosun Natural Sci. Vol. 8, pp. 209-213, 2015. https://doi.org/10.13160/ricns.2015.8.3.209
- M. Thirumurthy, "A docking study of newly found natural neuraminidase inhibitor: Erystagallin A", J. Chosun Natural Sci., Vol. 4, pp. 273-277, 2011.
- C. G. Gadhe, "Comparative modeling of human P-gp NBD2 and docking and binding mode analysis of 8-geranyl chrysin as a P-gp modulator", J. Chosun Natural Sci., Vol. 5, pp. 18-21, 2012. https://doi.org/10.13160/ricns.2012.5.1.018
- SYBYL Software, Tripos Associates Inc, St. Louis, USA, 2006.
- The PyMOL Molecular Graphics System, Version 1.7.4 Schrodinger, LLC.
- H. Matsunaga, S. Kamisuki, M. Kaneko, Y. Yamaguchi, T. Takeuchi, K. Watashi, and F. Sugawara, "Isolation and structure of vanitaracin A, a novel anti-hepatitis B viruscompound from Talaromyces sp.", Bioorg. Med. Chem. Lett., Vol. 25, pp. 4325-4328, 2015. https://doi.org/10.1016/j.bmcl.2015.07.067
- A. N. Jain, "Scoring functions for protein-ligand docking", Curr. Protein Pept. sc., Vol. 7, pp. 407-420, 2006. https://doi.org/10.2174/138920306778559395
- A. N. Jain, "Scoring non-covalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities", J. Comput. Aid. Mol. Des., Vol. 10, pp. 427-440, 1996. https://doi.org/10.1007/BF00124474